ArticleCureus2026
Beyond Hypothyroid Myopathy: Signal Recognition Particle (SRP)-Negative Necrotizing Dermatomyositis Unmasked by Anti-nuclear Matrix Protein 2 (Anti-NXP2) Positivity in a 60-Year-Old Woman With Hashimoto's Thyroiditis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Necrotizing dermatomyositis (NDM) represents a rare and severe inflammatory myopathy characterized by clinical features of dermatomyositis (DM) with histopathologic evidence of myofiber necrosis and minimal inflammatory infiltrates. Immune-mediated necrotizing myopathy is classically associated with anti-signal recognition particle (SRP) and anti-HMG-CoA reductase (HMGCR) antibodies; however, seronegative cases occur and may overlap with DM-specific autoantibodies such as anti-nuclear matrix protein 2 (anti-NXP2). Coexisting metabolic conditions, including hypothyroidism, may obscure the diagnosis. We report a 60-year-old woman with Hashimoto's thyroiditis who developed progressive proximal weakness and markedly elevated creatine kinase (CK) levels initially attributed to uncontrolled hypothyroidism. Despite thyroid hormone optimization, weakness persisted, and a progressive erythematous rash developed. Further evaluation revealed antinuclear antibody (ANA) positivity at 1:320, positive anti-Mi-2α/β, and markedly elevated anti-NXP2 antibodies, with negative anti-SRP and anti-HMGCR antibodies. Muscle biopsy demonstrated prominent myofiber necrosis with sparse inflammatory infiltrates, confirming NDM. High-dose corticosteroids and methotrexate resulted in gradual clinical improvement. Given the anti-NXP2 positivity, comprehensive malignancy screening was initiated. This case highlights the diagnostic challenge of distinguishing hypothyroid myopathy from inflammatory myopathy and expands the spectrum of anti-NXP2-associated disease to include SRP-negative necrotizing phenotypes. Persistent weakness or elevated CK levels despite thyroid correction should prompt evaluation for inflammatory myopathy, including myositis-specific antibodies and muscle biopsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.